

Enaminones in heterocyclic syntheses: part 5: isoniazid-enaminone a new organic synthon and tuberculostatic candidate.

Faida H. Ali Bamanie¹, A. S. Shehata², M. A. Moustafa^{3,4} and M. M. Mashaly^{*2}

¹Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, KSA.

²Department of Chemistry, Faculty of Science at (New) Damietta, Mansoura University, Egypt.

³Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.

⁴Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, KSA.

mashaly54321@mans.edu.eg

Abstract: condensation of nicotinic, isonicotinic acid hydrazides **1a,b** with 1,3-cyclohexanedione **2**, in water, using acetic acid as catalyst, afforded enaminone derivatives **3a,b**.

[Faida H. Ali Bamanie, A. S. Shehata, M. A. Moustafa and M. M. Mashaly. **Enaminones in heterocyclic syntheses: part 5: isoniazid-enaminone a new organic synthon and tuberculostatic candidate.** *Nat Sci* 2012; 10(12):7-10]. (ISSN: 1545-0740). <http://www.sciencepub.net>. 2

Keywords: hydrazine, nicotinic hydrazide, isoniazid, isoniazid-enaminone, tuberculosis.

Introduction

Isoniazid (isonicotinic acid hydrazide) **1a** is used as a veterinary antiactinomycotic agent and, most important, as a primary drug for the treatment of all types of tuberculosis [1-4a] and is, normally, given in high doses over long periods of time [2, 5]. Also, iproniazid (isonicotinic acid 2-isopropyl hydrazide) is applied as antidepressant [4b, 6].


Isoniazid **1a** itself has been reported to be carcinogenic in mice [2, 7] but the carcinogenic activity is probably due to the release of free hydrazine (H₂NNH₂) by the hydrolysis of **1a** according to **equation 1** [1, 2, 7]. Hydrazine, one of isoniazid's principle degradation products (**equation 1**) is a known carcinogen [1-3] and considerably, is more toxic than isoniazid [1, 2, 4c]. A very recent review [1] reported that "hydrazines cause DNA damage and gene mutations [8, 9]; hydrazine, methylhydrazine and related hydrazides (isoniazid is a hydrazide derivative of hydrazine) are known human carcinogens [10]; and hydrazines, hydrazides and hydrazones all show conventional structural alerts for genotoxic potential [11]".

On the other hand, Enaminones have proven to be versatile synthons for the synthesis of various heterocycles and natural products [12-14]. They are involved in the synthesis of, for example, pyridines, pyrimidines, pyrroles, indolizidines, quinolizidines and perhydroindoles, many of which are common motifs in alkaloid structures [12, 13]. Enaminones

are, also, frequently employed as building blocks for the preparation of highly functionalized mono-, bi- or larger- cyclic compounds of biological interest. In addition, some enaminones have been recognized as potential anticonvulsant [12, 15a-c] and analeptic [15d] compounds, with low toxicity.

Most of the syntheses of enaminones [12, 13], (especially, *via* condensation of 1,3-dicarbonyl compounds with ammonia, primary or secondary amines [16-21]; or with hydrazines [22]) are, usually, carried out in dry organic solvents, with continuous removal of water as a reaction by-product. However, we, herein, present a synthesis- in water- of the new enaminones **3a, b** (Scheme 1, Experimental). This work is in continuation of our recent interest in the field of (*Green Chemistry*), especially, in the direction of applying water -the safest and most economic solvent- in place of hazardous and expensive solvents in synthetic organic reactions [23, 24]. It is, also, in continuation of the work of one of our team on enaminones [25-28].

When isoniazid **1a** was allowed to react with the highly enolisable 1,3-cyclohexanedione **2**, through two hours of reflux conditions in water, in the presence of catalytic amount of acetic acid, the new enaminone derivative **3a** was obtained as a yellow fine crystalline matter in 80% yield of isolated product (Scheme 1, Experimental).



In the light of the above mentioned findings and results and as each of the new derivatives **3a,b** gathers or combines -in its chemical structure- between the functionality of cyclic enaminone and 2-substituted-hydrazide, it is worthy to suggest future studies to explore the potentiality of these new derivatives **3a, b** in both the fields of biological activity -especially, towards the different types of tuberculosis- and organic synthesis.

Experimental

Melting points were obtained on a Gallenkamp melting point apparatus (open capillary tubes) and were uncorrected; IR spectra were performed on a Jasco 4100 FTIR spectrophotometer (KBr pellet) at the Department of Chemistry, Faculty of Science at (New) Damietta, Mansoura University, Damietta branch, Egypt. ^1H NMR and ^{13}C NMR spectra were performed on a BRUKER (600 and 150 MHz, respectively) ultra shield Avance III Spectrometer at the Faculty of Science, King Abd-Elaziz University, Jeddah, K.S.A, using (TMS) as an internal stander and DMSO as a solvent. Chemical shifts were expressed as δ ppm. Microanalytical data were performed on a PERKIN-ELMER 2400 C, H, N Elemental Analyzer at the Microanalytical Unit, Cairo University, EGYPT.

3.1. Synthesis of N'-(3-oxocyclohex-1-enyl)isonicotinohydrazide (3a) and N'-(3-oxocyclohex-1-enyl)nicotinohydrazide(3b) (Scheme 1).

General procedure:

The hydrazide **1a** (or **1b**)(0.01mol) was dissolved in 30 ml of hot distilled water, while stirring. 1,3-cyclohexanedione **2** (0.01 mol) was, then, added, in portions, in the presence of 2 drops glacial acetic acid as a catalyst. A after complete addition of **2**, heating, while stirring, continued for two additional hours. The reaction solvent -water- was, then, removed using a rotary evaporator system. The evaporation residue was cooled to room temperature and, next, triturated with petroleum ether (40-60 °C) till a solid was obtained. The solid product was, then, crystallized from ethanol: water (1: 4) mixture to give **3a, b**, respectively.

N'-(3-oxocyclohex-1-enyl)isonicotinohydrazide (3a).

Yellow fine crystals: Yield: 80%; m.p: 186-8 °C; IR (KBr, cm^{-1}): γ = 3229, 3170 (NH); 1681 (CO); ^1H NMR (600 MHz, DMSO), δ , ppm = 10.83 (1H, s, -CONH-, hydrazide), 9.15 (1H, s, =C-NH-, enaminone), 8.80 (2H, d, H-2, H-6, pyridyl), 7.78 (2H, d, H-3, H-5, pyridyl), 4.96 (1H, s, -CO-CH=, enaminone), 2.41, 2.14, 1.87 (6H, 3x m, 3x-CH₂-, 3-oxocyclohex-1-enyl); ^{13}C NMR (150 MHz, DMSO), δ , ppm = 195.30 (CO, ketone), 164.00 (CO, hydrazide), 150.46 (CO, enaminone), 139.23, 121.23, 96.00 (-CO-CH=, enaminone), 36.55 (CH₂-CO), 25.60 (CH₂), 21.56 (CH₂-CH₂-CH₂).

Anal. Calcd for C₁₂H₁₃N₃O₂ (Mol.Wt: 231.25): C, 62.3; H, 5.67; N, 18.17; Found: C, 62.22; H, 5.35; N, 17.93.

N'-(3-oxocyclohex-1-enyl) nicotinohydrazide (3b)

Yellow fine crystals: Yield: 75%; m.p: 202-204 °C; IR (KBr, cm^{-1}): γ = 3243, 3178 (NH); 1677 (CO); ^1H NMR (600 MHz, DMSO), δ , ppm = 10.71 (1H, s, -CONH-, hydrazide), 9.12 (1H, s, =C-NH-, enaminone), 9.03 (1H, s, pyridyl), 8.77 (1H, d, pyridyl), 8.23 (1H, d, pyridyl), 7.56 (1H, m, pyridyl), 4.97 (1H, s, -CO-CH=, enaminone), 2.41, 2.14, 1.87 (6H, 3x m, 3x-CH₂-, 3-oxocyclohex-1-enyl); ^{13}C NMR (600 MHz, DMSO), δ , ppm = 195.27 (CO, ketone), 164.01 (CO, hydrazide), 152.6, 148.30, 135.19, 127.93, 123.72, 96.00 (-CO-CH-, enaminone), 36.56 (CH₂-CO), 25.69 (CH₂), 21.57 (CH₂-CH₂-CH₂).

Anal. Calcd for C₁₂H₁₃N₃O₂ (Mol.Wt: 231.25): C, 62.3; H, 5.67; N, 18.17; Found: C, 62.32; H, 5.55; N, 18.06.

References

- [1] D. P. Elder, D. Snodin, A. Teasdale, Journal of Pharmaceutical and Biomedical Analysis 54, 900-910 (2011).
- [2] A. Carlin, N. Gregory and J. Simmons, Journal of Pharmaceutical and Biomedical Analysis, 17, 885-890 (1998).
- [3] G. L. Mandell, M. A. Sande, in: A. G. Gillman, T. W. Rall, A. S. Nies, P. Taylor (Eds.), The Pharmacological Basics of Therapeutics, 8th ed., Pergamon, New Yourk, 1146-1149 (1990).

- [4] The Merck Index, Twelfth Edition, Susan Budavari, Editor, Merck Research Laboratories, Merck & CO., INC. Whitehouse Station, NJ (1996), (a) Item No. 5203, p. 885., (b) Item No. 5094, p. 871., (c) Item No. 4809, p. 816.
- [5] The Merck Manual of Diagnosis and Therapy, 16th ed., Merck, Rahway, NJ, (1992) 139-140., (through ref. 2).
- [6] J. Clayden, N. Greeves, S. Warren and P. Wothers, (Organic Chemistry), OXFORD University press INC, New Yourk, p. 29 (2008).
- [7] J. C. Arcos, Y. T. Woo, M. F. Argus, D. Y. Lai, Chemical Induction of Cancer, Academic Press, New York, p. 363, (1982).
- [8] S. Parodi, S. Deflora, M. Cavanna, DNA-damaging activity in vivo and bacterial mutagenicity of sixteen hydrazine derivatives as related quantitatively to their carcinogenicity, *Cancer Res.* 41 (1981) 1469–1482.
- [9] M. J. Zeilmaker, M.J. Horsfall, J.B. van Helten, Mutational specificities of environmental carcinogens in the *lacI* gene of *Escherichia coli* H. V: DNA sequence analysis of mutations in bacteria recovered from the liver of Swiss mice exposed to 1,2-dimethylhydrazine, azoxymethane, and methyl azoxymethanol acetate, *Mol. Carcinog.* 4,180-188 (1991).
- [10] J. A. Knottnerus, N-Methylhydrazine, Evaluation of the Carcinogenicity and Genotoxicity, Dutch Expert Committee on Occupational Standards, A Committee of the Health Council of the Netherlands, Nr 2002/07OSH, The Hague, 16th April 2002.
- [11] K. Sawatari, Y. Nakanishi, T. Matsushimi, Relationships between chemical structures and mutagenicity: a preliminary survey for a database of mutagenicity test results of new work place chemicals, *Ind. Health* 39, 341–345 (2001).
- [12] G. Negri, C. Kascheres and A. J. Kascheres, *J. Heterocyclic Chem.* 41, 461-491 (2004).
- [13] B. Stanovnik and J. Svete, *Chem. Rev.*, 104, 2433-2480 (2004).
- [14] B. Stefane and S. Polanc, *New J. Chem.*, 26, 28-32 (2002).
- [15] (a) I. O. Edafiogho, C. N. Hinko, H. Chang, J. A. Moore, D. Mulzac, J. M. Nicholson and K. Scott, *J. Med. Chem.* 35, 2798 (1992); (b) K. R. Scott, I. O. Edafiogho, E. L. Richardson, V. A. Farrar, J. A. Moor, E. I. Tietz, C. N. Hinko, H. Chang, A. El-Assadi and J. M. Nicholson, *J. Med. Chem.*, 36, 1974 (1993); (c) K. R. Scott, G. O. Rankin, J. P. Stables, M. S. Alexander, I. O. Edafiogho, V. A. Farrar, K. R. Kolen, J. A. Moor, L. D. Smis and A. D. Tonnu, *J. Med. Chem.* 38 (1995) 4033; (d) Hoffmann-La Roche, Ger. Pat. (DRP), 614, 195 (1935); *Chem. Abstr.*, 29, 5995 (1935).
- [16] K. R. Scott, G. O. Rankin, J. P. Stables, M. S. Alexander, I. O. Edafiogho, V. A. Farrar, K. R. Kolen, J. A. Moore, L. D. Sims and A. D. Tonnu, *J. Med. Chem.*, 38, 4033 (1995). *Chem. Abstr.*, 123, 313499h (1995).
- [17] I. O. Edafiogho, J. A. Moore, V. A. Farrar, J. M. Nicholson and K. R. Scott, *J. Pharm. Sci.*, 83, 79 (1994).
- [18] K. R. Scott, I. O. Edafiogho, E. L. Richardson, V. A. Farrar, J. A. Moore, E. I. Tietz, C. N. Hinko, H. Chang, A. El-Assadi and J. M. Nicholson, *J. Med. Chem.*, 36, 1947 (1993); *Chem. Abstr.*, 119, 116884w (1993).
- [19] I. O. Edafiogho, C. N. Hinko, H. Chang, J. A. Moore, D. Mulzac, J. M. Nicholson and K. R. Scott, *J. Med. Chem.*, 35, 2798 (1992). *Chem. Abstr.*, 117, 69477n (1992).
- [20] J. V. Greenhill, I. Chaaban and P. J. Steel, *J. Heterocyclic Chem.*, 29, 1375 (1992).
- [21] B. V. Lichitsky, S. N. Ivanov, A. A. Dudinov, S. A. Woznesensky and M. M. Krayushkin, *Russ.Chem. Bull., Int. Ed.*, 50, 2428 (2001).
- [22] B. V. Lichitsky, V. N. Yarovenko, I. V. Zavarzin and M. M. Krayushkin, *Russ. Chem. Bull., Int. Ed.*, 49, 1251 (2000).
- [23] F. H. A. Bamanie, A. S. Shehata, M. A. Moustafa and M. M. Mashaly, *Journal of American Science*, 8, 481-485 (2012).
- [24] A. S. Shehata, Faida H. Ali Bamanie, M. A. Moustafa and M. M. Mashaly, *Journal of American Science*, 7, 240-242 (2011).
- [25] M. M. Mashaly and M. Hammouda, *Z. Naturforsch.*, 54b, 1205-1209 (1999).
- [26] M. Hammouda, M. M. Mashaly and A. A. Fadda, *Arch. Pharm. Res.*, 18, 213-214 (1995).
- [27] M. Hammouda, M. M. Mashaly and E. M. Afsah, *Pharmazie* 49, 365-366 (1994).
- [28] S. R. El-Gogary, M. M. Mashaly and T. R. Kosbar, "Enaminones in heterocyclic syntheses: part 4: a new one step synthetic route to pyrrolo [3,4-b]pyridine and convenient syntheses of 1,4-dihydropyridines and 1,1'-(1,4-phenylene) bis(1,4-dihydropyridine)s., accepted on 23-Dec.-2011 by *J. Heterocyclic Chem.*